pdufa
saveRegeneron Pharmaceuticals Inc — dupilumab (PDUFA)
community read0 votes
Therapy area: Dermatology. Indication: Chronic Urticaria
Data sources
globaldata
Found something off?
drug timeline · 8
- phase 2 completionBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)Apr 30, 2026 · 160d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalApr 16, 2026 · 174d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalFeb 23, 2026 · 226d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalJun 18, 2025 · 476d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalApr 17, 2025 · 538d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalApr 16, 2025 · 539d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalSep 27, 2024 · 740d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalSep 12, 2024 · 755d ago
same company · ±60 days · 4
- earningsREGENERON PHARMACEUTICALS, INC. earningsApr 29, 2026
- phase 2 completioncemiplimab: Regeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)Apr 30, 2026
- approvaldupilumab: DUPIXENT (DUPILUMAB) — FDA approvalApr 16, 2026
- approvalEYLEA HD: EYLEA HD (AFLIBERCEPT) — FDA approvalApr 2, 2026
related news · 4
- oncliveCases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
- statSTAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more
- biopharma diveFDA approves Regeneron’s hearing loss gene therapy
- biopharma diveSanofi posts upbeat sales as R&D pressure builds
comments(0)
5-min edit window · permanent after that